Full transcript of "Face the Nation with Margaret Brennan," Dec. 7, 2025

Treasury Secretary Scott Bessent defended a stronger-than-expected economy—citing consecutive ~4% GDP quarters and a projected ~3% full-year real GDP—while noting PCE inflation near 2.9% and imported-goods inflation around 1.8%, and attributing current price pressure mainly to services. Policy moves with direct sectoral implications include a China trade agreement committing to ~12.5 million metric tons of soybeans this crop year (25 million metric tons annually over the next three years), an announced short-term bridge payment for farmers, and a new child “Trump Account” program seeding $1,000 for U.S. children born 2025–2028. Regulatory risk elevated after ACIP’s 8–3 vote to delay the newborn hepatitis B dose (prompting biotech sector weakness) and reported internal FDA shifts away from immunobridging and toward stricter approval requirements, creating heightened uncertainty for vaccine development and insurers/state compliance.

Analysis

Market Structure: Policy noise (Treasury messaging, trade soy purchases, ACIP vaccine shifts) creates bifurcation: large diversified pharma (e.g., PFE) and broad ag exporters gain relative footing while pure-play vaccine developers and small-cap biotechs face demand compression. Expect 3–6 month rotation into defensives and ags (soybean volumes +12–15% signaled) with retail pockets (toys, beef) showing idiosyncratic pricing power; imported goods CPI pressure is subdued vs. services inflation.

Risk Assessment: Near-term tail risks include accelerated regulatory changes (FDA/ACIP within 30–90 days) that could remove immunobridging, triggering a 20–40% rerating of vaccine-adjacent small caps; geopolitical operational risk from aggressive maritime strikes could spike oil and defense volatility for days–weeks. Hidden dependencies: state-level rejection of ACIP guidance will fragment payer coverage and create permanent demand loss for seasonal vaccine update business models over 12–36 months.

Trade Implications: Favor size and cash-flow stability: overweight PFE on 3–7% pullback (6–12 month target +10–15% via stable vaccine/portfolio revenue) and go long soybean exposure (SOYB or ADM/BG) targeting +10–20% over 3–9 months as China cadence continues. Short small/mid-cap vaccine-exposed biotech (reduce XBI weight by ~20%) using protective put spreads; use 2–3 month put spreads on IBB/XBI to express policy-driven downside while limiting capital at risk.

Contrarian Angles: Consensus assumes uniform biotech selloff; that overlooks names with non‑vaccine franchises (oncology, rare disease) that should decouple—buy select mid‑caps with >60% non‑vaccine revenue on 15–25% dislocation. Also, if ACIP credibility collapses, large incumbents (PFE) with commercial relationships to pediatrics insurers could capture market share — asymmetric upside capped risk vs concentrated vaccine developers.

Key Decisions for Investors

• Establish a 2–3% portfolio long in PFE on any 3–7% pullback; time horizon 6–12 months, target total return +10–15% as large-cap diversification and non-vaccine franchises re-rate.
• Buy soybean exposure: 2% position in SOYB or 2–3% in ADM/Bunge (ADM, BG) aiming for +10–20% over 3–9 months given China purchase cadence (12.5m mt now, 25m mt next 3 years); trim if soy futures rally >20%.
• Reduce XBI weight by ~20% (or outright trim small-cap vaccine-exposed names) and buy 45–60 day put spreads on IBB or XBI (sell nearer OTM puts, buy slightly farther OTM) to cost-effectively hedge 20–40% downside risk around FDA/ACIP regulatory windows.
• Initiate a pair trade: long 1–2% position in large-cap non‑vaccine biotech/pharma names with >60% non-vaccine revenue (select names) and short equivalent dollar exposure in pure-play vaccine developers (small caps) for 6–12 months; rebalance if regulatory clarity emerges within 30–90 days.
• Monitor and act on three catalysts in next 30–90 days: (1) HHS/FDA release of case-level vaccine safety analyses (threshold: public evidence of causal links → accelerate hedges), (2) ACIP follow-up guidance or state law changes (if >10 states decouple, increase short-biotech exposure), (3) China soybean purchase timing slips by >60 days (if delayed, reduce ag longs).